Aug 10 (Reuters) - Appili Therapeutics Inc APLI.V :
* FDA CLEARS APPILI THERAPEUTICS TO EXPAND ITS PHASE 2 CLINICAL TRIAL OF FAVIPIRAVIR FOR THE POTENTIAL PREVENTION OF COVID-19 AT U.S. LONG-TERM CARE FACILITIES
* APPILI THERAPEUTICS INC - INTENDS TO ENROLL UP TO 760 PARTICIPANTS IN FAVIPIRAVIR PHASE 2 CLINICAL TRIAL ACROSS BOTH U.S. AND IN CANADA